Perspective Therapeutics, Inc. · AMEX:CATX
Perspective Therapeutics — Investor Presentation (September 2023)
45 slides from Perspective Therapeutics's investor presentation, Sep 5, 2023
Slide 1: Corporate Presentation
PERSPECTIVE THERAPEUTICS Corporate Presentation NYSE: CATX
Slide 2: Legal Disclaimers
Legal Disclaimers This presentation contains forwardiooking statements within the meaning ofthe Unted States Prvate Secures Ligation Reform Act of 1995. Statements n this presentation that are not ‘statements of historical fact are foruarclockng statements. Words such as “may,” “wil,” “shoul,” “expe
Slide 3: Investment Highlights
Investment Highlights + Radiopharmaceutical company focus on pan-cancer opportunities + Two clinical-stage programs with robust pre-clinical pipeline + VMT-o-NET - First in human trial ongoing for neuroendocrine tumors + VMT-01 - Targeting the melanocortin 1 receptor (MC1R) for melanoma + Proprietar
Slide 4: Discovery Platform Gives Broad Proprietary Pipeline
Discovery Platform Gives Broad Proprietary Pipeline Human Clinical | Human Program Indication Discovery! Imaging | Therapy | Phase1 | Phase2 | Phase3 Neuroendocrine cancer VMT-aNET Pheochromocytomas, paragangliomas ‘Small cell lung cancer PO > > eee Mesanoma (MCR Pe Ll Ld L__d => L__4 \VMT-02(PETage
Slide 5: Multiple Near-Term Data Readouts
Multiple Near-Term Data Readouts Pipeline = tndeton ase er ne Poona magepsted era teauoconeestoun sth FS {Vzncieeenaonsy these Looe atin a Ooee isnson Ctr nh fers ny a omy ec anaore aye ‘/ansie exten sy hase 102 Exaltin n canto rans in tlannons pein mou Nuon prea nt L 4 Emery vce rate cancer Crwoome
Slide 6: Radiopharmaceuticals are a Pillar of Oncology Treatment with Pan-Cancer Opportunities
Radiopharmaceuticals are a Pillar of Oncology Treatment with Pan-Cancer Opportunities Molecularty Targeted + Radioligands can precisely deliver radiation directly to cancer cells reducing off-target effects Radiation + Provenpillar of cancer treatment + Molecular imaging companion diagnostics enable
Slide 7: Targeted α-Particle Radiotherapy: A New Class of Oncology Therapeutics
Targeted a-Particle Radiotherapy A New Class of Oncology Therapeutics
Slide 8: Perspective's Radiopharmaceutical Optimization Process
Perspective’s Radiopharmaceutical Optimization Process Targeting Peptide ngineered for cance cific receptors to ensure highly directed uptake in cancer only Linker Selected to assist peptide binding and optimize clearance from blood and healthy tissues Isotope >b for SPECT imaging or >» for alpha pa
Slide 9: Lead-212: The Optimal Therapeutic Isotope
Lead-212 (?12Pb): The Optimal Therapeutic Isotope Greater Therapeutic Energy Expected to Improve Outcome with Better Safety Emission Profile Beta Beta Alpha Alpha Potent Half Life 8 days 67 days 10 days 0.46 days Rapid Clearance Off Target Toxicity Risk _| Very high Low High Low Best ‘Supply High Lo
Slide 10: Peptides are ideal ligands for radiopharmaceutical therapy
Peptides are ideal ligands for radiopharmaceutical therapy Monoclonal antibodies Kinetics Tumor penetration: tow Clearance: Hepatobiliay (Iver) Biological Lite: Long | Target afin High Accumulation time: Extended 3 Stability Questionable } Production . S Manufacturing Complex biological sceacmiaad e
Slide 11: Lead (Pb): The Ideal Theranostic Isotope
Lead (Pb): The Ideal Theranostic Isotope Ideal Theranostic Requirements Solutions: 2°72!2Pp & Perspective Chelator Ideal agreement between imaging and therapeutic compounds (4°) Readilyavailable isotope e@ Ideal chelator () Rapid clearance from blood © High tumorretention @24 hours, Shortt-% gives r
Slide 12: Chelator Optimized for 212/203Pb
Chelator Optimized for 212/293Pb q 9 fo) fo) ot . of HN. HO. 4 Net 2-| "2 Ue Net 2+ ine Net 0 Improves: radiolabeling 7 renal clearance 2: ae P too TN receptor binding ‘ou Wk Mo internalization af NH> yon TCMC Commeraly ral Generic chelators leave formal charge at chelator/radiometal coupling (posit
Slide 13: Theranostics: Targeting Therapies to Patients Likely to Respond
Theranostics: Targeting Therapies to Patients Likely to Respond Tyg = 52h Imaging (See it Dosimetry Linker convenient imaging surrogate Targeting Ligand Therapeutic (Treatit) Cancer 23Pb canbe O used to Linker 4 conveniently Targeting Ligand establish 2#2Pb ° pharmacokinetics PERSPECTIVE THERAPEUTIC
Slide 14: Neuroendocrine Tumors: VMT-α-NET
Neuroendocrine Tumors: VMT-c-I Targeting the somatostatin receptor neuroendocrine- type cancers
Slide 15: VMT-α-NET Currently In Phase 1/2a Studies
VMT-a-Net Currently In Phase1/2a Studies i Targeting somatostatin receptor type 2 (SSTR2) for the imaging and treatment of neuroendocrine tumors Initiated first-in-human imaging (2021) & therapy (2022) under compassionate use Fast Track Designation received October 2022 Open IND for Therapeutic Tria
Slide 16: SSTR2 Positive Tumors
SSTR2 Positive Tumors Neuroendocrine tumors (NETS) + Neuroendocrine cells are specialized cells that secrete hormones and other bioactive substances + Neuroendocrine cells are found throughout the body + Often grow in the pancreas or other areas of the gut, such as the stomach, small intestine, rect
Slide 17: VMT-α-NET Target Indication: Neuroendocrine Tumors (NETs)
VMT-a@-NET Target Indication: Neuroendocrine Tumors (NETS) Significant unmet need: + ~12K newdiagnoses annually in the US! it inte * Treatment depends on the type of tumor. Some approaches may include surgery. radiation, and chemotherapy * ~175,000+ people are living with this diagnosis in the US! *
Slide 18: Preclinical Imaging Demonstrates Superiority of Perspective's Platform Technology
Slide 19: 203Pb SPECT Imaging Reveals Favorable VMT-α-NET Properties
203Pb SPECT Imaging Reveals Favorable VMT-a-NET Properties Rapid Tumor Targeting and Renal High Tumor Retention 1.5 hrs ‘SPECT/CT VW J 22hrs +‘? & e? SPECT/CT - - . + Tumors visible within 4 hour q d high intensity above background oo * Unbound drug in bladder within 1 hour, low renal retention ee 1
Slide 20: 1st Patient with [212Pb]VMT-α-NET
15‘ Patient with [?47Pb]VMT-a-NET Significant Tumor Response After a Single Dose Tumor Before Ml Treatment Tumor After1 Of Dose THERAPEUTICS PERSPECTIVE
Slide 21: Preclinical Data
Preclinical Data VMT-a-NET shows improvements vs Standard of Care [277Lu]DOTATATE i i ! fof f Detroit [?22Pb] VMT-c-NET (120 Ci) [?!2Pb] VMT-o-NET (4X30 pCi) nyspostteatnent {} ore Aeminitrea t PERSPECTIVE eer .
Slide 22: Phase 1/2a [212Pb]VMT-α-NET mTPI-2
Phase 1/2a [?!?Pb]VMT-a-NET mTPI-21[NCT05636618] To determine the MTO/MFD of (=Pb]VMTEaeNET Primary Objective ea FDA approved SSTR2 PET/CT Population Escalation ~ 10:32 Expansion n = 20-100 Unresectable or metastatic SSTR2-positive neuroendocrine tumors PRAT nave Therapeutic Dose 2.5-10 mCi dose esc
Slide 23: VMT-α-NET Clinical Development Plan: All Neuroendocrine Tumor Types
VMT-a-NET Clinical Development Plan: All Neuroendocrine Tumor Types Data expected 2023 Compassionate Image-Guided Therapy Phase 1/2a Dose Escalation Study Clinical Sites: Multiple global sites Clinical Site: Multiple in US; Mayo, Ul and UW + ‘Subjects: All NETS (refractory & radiotherapy naive) ‘Sub
Slide 24: Melanoma Program: VMT01/02
Melanoma Program: VMT01/02 Using the melanocortin receptor MC1R to target melanoma for imaging and therapy
Slide 25: VMT01 Currently In Phase 1/2a Studies
VMTO1 Currently In Phase1/2a Studies 5 . “ap 4 "ke ~ FA Targeting melanocortin 1 receptor (MC1R) @ Preclinical combination data (published) resulted in $2m NIH SBIR Grant Results from completed Phase 1 imaging study presented Q2 2023 Study was conducted at the Mayo Clinic Rochester Open IND for Ther
Slide 26: Metastatic Melanoma
Metastatic Melanoma Brain Lymph nodes Lungs skin (Primary) Liver [?*°Pb]VMF-01 target indication: MCIR-positive melanoma + Market opportunity of $8 billion in 2028" + Significant unmet need in the US: + ~100K new diagnoses annually? + ~8,000 people die from melanoma every year? + Treatment depends o
Slide 27: Preclinical microSPECT Whole body planar SPECT/CT
@: Preclinical microSPECT Whole body planar SPECT/CT PERSPECTIVE THERAPEUTICS
Slide 28: VMT01/02 Demonstrated Complete Responses in Multiple Animal Tumor Models
VMT01/02 Demonstrated Complete Responses in Multiple Animal Tumor Models Key Takeaways Single dose of VMTO1 significantly arrested if melanoma tumor growth and extended survival: + High response rates in multiple tested 100+ Immunodeteient human ‘melanamaxeragatt mode! models 3 004 BRAF postive = +
Slide 29: Phase 1/2a [212Pb]VMT01-T101 mTPI-2
Phase 1/2a [?*?7Pb]VMTO1-T101 mTPI* [NCT05655312] Therapeutic Dose Primary Objective To determine the MTD/MFD of (Pb]VMTOLTI02 (RP2D) *8Pb]VMTOL SPEC/CT or [*Ga]VMTO2 PET/CT Unresectable of metastatic MCAR positive Melanoma ‘2 15 mCi dose escalation with fixed dosing every 8 weeks for upto 3 cycles
Slide 30: VMT01 Clinical Development Plan — Metastatic Melanoma
VMTO1 Clinical Development Plan — Metastatic Melanoma Data expected 2023 Completed Phase 1 Imaging Study Phase 1/2a Dose Escalation Study Clinical Site: Mayo Clinic (Rochester, MN) Clinical Site: Sites enrolling, expansion to 15 US sites ‘Subjects: 7: Stage lll/IV unresectable melanoma Subjects: ~30
Slide 31: Controlling the Therapeutic Isotope: VMT-α-GEN
Controlling the Therapeutic Iso’ VMT-a-GEN Delivering therapies to a broader grt
Slide 32: 212Pb Supply via Reusable Desktop Isotope Generator
212Pb Supply via Reusable Desktop Isotope Generator \VMT-a-GEN Small, Elegant ?12Pb Isotope Generator + Extensive feedstock from nuclear 3 + Integrated lead shielded and mining waste material containment + Long-term supply contract secured (ay + Simple inletand outlet ports ith US DOE “ + Radioactiv
Slide 33: Manufacturing Options Overview — Current and Future Supply
Manufacturing Options Overview — Current and Future Supply eee | eo pres | ontpoed for22Pb Generator etutew for22PD fad = + Commercial supply will require the use of an isotope production system of larger scale than the current 24Ra/?#2Pb generators + The current isotope separation process remains h
Slide 34: Commercialization of 212Pb-labeled Finished Radiopharmaceuticals
Commercialization of 212Pb-labeled Finished Radiopharmaceuticals * | Location Coralville, 1A Sim New York. NY 75m Los Angeles, CA 46m Austin, 1X 32m Atlanta, GA 57m Central Florida, FL. 25m million people within a one half-life (11. hp) delivery radius? + Products can also be driven fur Circles repr
Slide 35: Corporate Overview
Corporate Overview
Slide 36: Management Team
Management Team Deep Radiotherapy and Development Experience e e e Thijs Spoor Jonathan Hunt Markus Puhlmann MD MBA Chief Executive Chief Financial Chief Medical Officer Officer Officer 20+ yearsof expertise 20+ yearsof expertise 20+ years of oncology jotechnology in financial controls drug developm
Slide 37: Intellectual Property
Intellectual Property aa Fully Licensed University/Perspective owned IP (\/ 3 provisional patents + Composition of Matter and Use VMT-c-NET, chelator, Isotope generator and novel pan-cancer product + USA, EU, Australia 5 issued patents- Expiry in 2037 + Composition of matter and use on melanoma targ
Slide 38: Slide 38
Slide 39: Appendix
Appendix
Slide 40: α-Particles Have Superior Tumor Killing Properties vs. β-Particles
@-Particles Have Superior Tumor Killing Properties vs. 6-Particles More Powerful Effects Than Approved B Therapy Higher atomic mass Lethal double-stranded DNA breaks DNA repair mechanisms overwhelmed Precision Delivery Provides Targeted Cell Destruction Deposit energy over 3-5 cell diameters vs. bet
Slide 41: Isotope: Decay chain — Biological implications
Isotope: Decay chain — Biological implications 22°Ac Decay Series seo: pc — ~ eeumafaa nn wcosenay| ane ene a on Alpha-particle emission imparts sufficient “recoil” energy to break chemical bonds. PERSPECTIVE AY pesree?
Slide 42: Isotope: Decay chain — Product implications
Isotope: Decay chain — Product implications Post final radiolabeling and purification, alpha and beta emitting daughters of 2?°Ac build up fast. ‘Ac-225 Decay and Daughter Ingrowth AC225 mFr221 MAL2IT mBL213 = T1209 mPO-213 Dose Vial aoe 6000 Radiometals: |e more unlabeled daughter activity in about
Slide 43: Isotope: Decay chain and chelator selection
Isotope: Decay chain and chelator selection 212Pb Decay Series ay Parent Material y “188 | 4Ral™Pb Generator ay Ri Pe 14min B 034s ch 66%" al Po 2B 208Ph O.1s 61 min| B | stable ay Be ay a 2p 2067 1th 3min (22Pb]PSct 2PSC = Lead (Pb)-Specific Chelator PERSPECTIVE THERAPEUTICS
Slide 44: Clinical Trial Principal Investigators
Clinical Trial Principal Investigators Renowned Experts in Radiotherapy Development ‘Yusuf Menda MD Professor of Radiology Chair, PET/MR R&D Chair, Division of Nuclear Medicine Project Leader Neuroendocrine Tumor SPORE University of lowa - lowa City, IA Associate Professor Departments of Radiology a
Slide 45: Slide 45
Perspective Therapeutics — Investor Presentation (September 2023) on 6ix